BRPI0921469A2 - proteínas de ligação que inibem a interação com o receptor de vegf-a - Google Patents

proteínas de ligação que inibem a interação com o receptor de vegf-a

Info

Publication number
BRPI0921469A2
BRPI0921469A2 BRPI0921469A BRPI0921469A BRPI0921469A2 BR PI0921469 A2 BRPI0921469 A2 BR PI0921469A2 BR PI0921469 A BRPI0921469 A BR PI0921469A BR PI0921469 A BRPI0921469 A BR PI0921469A BR PI0921469 A2 BRPI0921469 A2 BR PI0921469A2
Authority
BR
Brazil
Prior art keywords
vegf
receptor
binding proteins
inhibit interaction
inhibit
Prior art date
Application number
BRPI0921469A
Other languages
English (en)
Inventor
Hans Kaspar Binz
Michael Tobias Stumpp
Patrik Forrer
Original Assignee
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag filed Critical Molecular Partners Ag
Publication of BRPI0921469A2 publication Critical patent/BRPI0921469A2/pt
Publication of BRPI0921469B1 publication Critical patent/BRPI0921469B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4703Inhibitors; Suppressors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/515Angiogenesic factors; Angiogenin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0921469-0A 2008-11-03 2009-11-03 Proteínas de ligação que inibem a interação com o receptor de vegf-a, composição farmacêutica BRPI0921469B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08168166.0 2008-11-03
EP08168166 2008-11-03
PCT/EP2009/064483 WO2010060748A1 (en) 2008-11-03 2009-11-03 Binding proteins inhibiting the vegf-a receptor interaction

Publications (2)

Publication Number Publication Date
BRPI0921469A2 true BRPI0921469A2 (pt) 2016-01-12
BRPI0921469B1 BRPI0921469B1 (pt) 2022-01-18

Family

ID=40149742

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921469-0A BRPI0921469B1 (pt) 2008-11-03 2009-11-03 Proteínas de ligação que inibem a interação com o receptor de vegf-a, composição farmacêutica

Country Status (15)

Country Link
US (2) US8901076B2 (pt)
EP (2) EP2358746B1 (pt)
JP (2) JP5954990B2 (pt)
KR (1) KR101698362B1 (pt)
CN (2) CN102272148A (pt)
AU (1) AU2009319204B2 (pt)
BR (1) BRPI0921469B1 (pt)
CA (1) CA2742241C (pt)
DK (1) DK2358746T3 (pt)
ES (1) ES2836948T3 (pt)
IL (1) IL212589A (pt)
MX (2) MX2011004649A (pt)
NZ (1) NZ592591A (pt)
RU (2) RU2650765C1 (pt)
WO (1) WO2010060748A1 (pt)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9829494B2 (en) 2005-12-01 2017-11-28 Adrenomed Ag Methods of treatment using ADM antibodies
WO2007116360A2 (en) 2006-04-07 2007-10-18 The Procter & Gamble Company Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
AU2014243418B2 (en) * 2010-04-30 2016-09-22 Molecular Partners Ag Modified binding proteins inhibiting the VEGF-A receptor interaction
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
CA2818990C (en) * 2010-11-26 2021-06-15 Molecular Partners Ag Designed repeat proteins binding to serum albumin
EP2702069A4 (en) 2011-04-29 2015-04-29 Janssen Biotech Inc IL4 / IL13 BINDING REPEAT PROTEINS AND USES THEREOF
WO2012172054A1 (en) 2011-06-16 2012-12-20 Scil Proteins Gmbh Modified multimeric ubiquitin proteins binding vegf-a
DK2780371T3 (en) 2011-11-16 2019-02-25 Adrenomed Ag ANTI-ADDRENOMEDULLIN (ADM) ANTIBODY OR ANTI-ADM ANTISTOFFRAGMENT OR ANTI-ADM NON-IG TEMPLATE FOR REGULATING LIQUID BALANCE OF A PATIENT WITH A CHRONIC OR ACUTE DISEASE
EP2594587B1 (en) 2011-11-16 2014-05-21 AdrenoMed AG Anti-Adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig protein scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
PT2780370T (pt) 2011-11-16 2019-10-30 Adrenomed Ag Anticorpo anti-adrenomedulina (adm) ou fragmento anticorpo anti-adm ou estrutura de anticorpo anti-adm não ig para utilização na terapia de uma doença aguda ou condição aguda de um paciente para estabilizar a circulação
PL2594588T3 (pl) 2011-11-16 2014-11-28 Adrenomed Ag Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zastosowania w terapii
WO2013072509A1 (en) 2011-11-16 2013-05-23 Adrenomed Ag Adrenomedullin assays and methods for determining mature adrenomedullin
PT2780369T (pt) 2011-11-16 2019-06-18 Adrenomed Ag Anticorpo antiadrenomedulina (adm) ou fragmento de anticorpo anti-adm ou uma estrutura não ig anti-adm, para a prevenção ou a redução de disfunções de órgãos ou de insuficiências de órgãos num doente com uma doença aguda ou crónica ou com uma patologia aguda
CN103308670B (zh) 2012-03-08 2017-06-09 思芬构技术有限公司 用于预测对象患糖尿病和/或代谢综合征的风险的方法
CN103308673B (zh) 2012-03-08 2017-05-31 思芬构技术有限公司 用于预测雌性对象中发生心血管事件的风险的方法
CN103308689B (zh) 2012-03-08 2017-04-12 思芬构技术有限公司 用于预测雌性对象中患上癌症的风险或诊断癌症的方法
ES2753135T3 (es) 2012-05-07 2020-04-07 Allergan Inc Método de tratamiento de DMAE en pacientes resistentes a terapia anti-VEGF
BR112014032316A2 (pt) * 2012-06-28 2017-06-27 Molecular Partners Ag proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta
AU2013100071C4 (en) * 2012-07-03 2013-05-02 Novartis Ag Device
JOP20200175A1 (ar) 2012-07-03 2017-06-16 Novartis Ag حقنة
AU2012101678B4 (en) * 2012-07-03 2013-01-24 Novartis Ag Use of device
EP2890389A1 (en) * 2012-08-28 2015-07-08 Novartis AG Use of a vegf antagonist in treating ocular vascular proliferative diseases
JP6307509B2 (ja) 2012-10-02 2018-04-04 シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 腎機能の診断若しくは監視又は腎機能障害の診断方法
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
US20150346222A1 (en) 2013-01-08 2015-12-03 Sphingotec Gmbh Fasting levels of growth hormone as a predictive marker of cardiovascular risk
CN105143270B (zh) * 2013-02-26 2019-11-12 罗切格利卡特公司 双特异性t细胞活化抗原结合分子
WO2014151725A1 (en) * 2013-03-14 2014-09-25 Allergan, Inc. Composition of a sustained-release delivery and method of stabilizing proteins during fabrication process
SG10201800309SA (en) 2013-03-20 2018-02-27 Sphingotec Gmbh Adrenomedullin to guide therapy of blood pressure decline
FR3004650B1 (fr) * 2013-04-22 2015-05-29 Affilogic Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation
WO2014191574A1 (en) 2013-05-31 2014-12-04 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor
EP3010526A1 (en) 2013-06-20 2016-04-27 Novartis AG Use of a vegf antagonist in treating macular edema
WO2014203182A1 (en) 2013-06-20 2014-12-24 Novartis Ag Use of a vegf antagonist in treating choroidal neovascularisation
JP2016522248A (ja) 2013-06-20 2016-07-28 ノバルティス アーゲー ポリープ状脈絡膜血管症の治療
MX2016000385A (es) * 2013-07-11 2016-04-29 Novartis Ag Uso de un antagonista vegf en el tratamiento de la retinopatia de la prematuridad.
MX2016000384A (es) 2013-07-11 2016-04-29 Novartis Ag Uso de un antagonista de vegf en el tratamiento de trastornos coriorretinianos neovasculares y de permeabilidad en pacientes pediatricos.
KR20230152151A (ko) 2013-07-12 2023-11-02 이베릭 바이오, 인크. 안과적 질환을 치료하거나 예방하기 위한 방법
EP3065761B1 (en) * 2013-11-05 2020-01-08 Allergan, Inc. Method of treating conditions of the eye with an anti-vegf darpin
EP3143044A1 (en) 2014-05-12 2017-03-22 Formycon AG Pre-filled plastic syringe containing a vegf antagonist
US20160097781A1 (en) 2014-10-01 2016-04-07 Sphingotec Gmbh Method for stratifying a female subject for hormone replacement therapy
ES2953482T3 (es) 2015-04-02 2023-11-13 Molecular Partners Ag Dominios de repetición de anquirina diseñados con especificidad de unión para la albúmina sérica
US11598781B2 (en) 2015-04-24 2023-03-07 Sphingotec Gmbh Method for predicting the risk of incidence of chronic kidney disease
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
MX2018006139A (es) 2015-11-18 2019-03-14 Sio2 Medical Products Inc Envase farmaceutico para formulaciones oftalmicas.
US20180326126A1 (en) 2015-11-18 2018-11-15 Formycon Ag Pre-filled plastic syringe containing a vegf antagonist
WO2017087798A1 (en) 2015-11-18 2017-05-26 Formycon Ag Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
AU2017213103B2 (en) 2016-01-26 2022-08-11 Formycon Ag Liquid formulation of a VEGF antagonist
CN109073660B (zh) 2016-02-29 2022-10-28 麦恩泰科特有限公司 可用于治疗湿性年龄相关性黄斑变性的预测性标志物
EP3854817A1 (en) 2016-04-21 2021-07-28 4TEEN4 Pharmaceuticals GmbH Methods for determining dpp3 and therapeutic methods
MA45493A (fr) 2016-06-27 2019-05-01 Aicuris Anti Infective Cures Gmbh Inhibiteurs d'entrée de hcmv.
ES2948446T3 (es) 2016-07-08 2023-09-12 Sphingotec Gmbh Adrenomedulina para la valoración de la congestión en un sujeto con insuficiencia cardiaca aguda
EP3487518A4 (en) 2016-07-20 2020-08-12 Aerpio Therapeutics LLC HUMANIZED MONOCLONAL ANTIBODIES TARGETING VE-PTP (HPTP-SS)
MX2019003298A (es) 2016-09-22 2019-09-26 Molecular Partners Ag Proteinas de union recombinantes y sus usos.
EP3309550A1 (en) 2016-10-12 2018-04-18 sphingotec GmbH Method for the detection of apolipoprotein e4
EP3339324A1 (en) 2016-12-22 2018-06-27 sphingotec GmbH Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
RU2762059C2 (ru) 2016-12-16 2021-12-15 Адреномед Аг Антитело против адреномедуллина (adm), или фрагмент анти-adm антитела, или анти-adm не-ig каркас для применения при вмешательстве и терапии гиперемии у пациента
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
US20200237997A1 (en) 2017-05-24 2020-07-30 Formycon Ag Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
US20200171244A1 (en) 2017-05-24 2020-06-04 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
US20200182885A1 (en) 2017-05-30 2020-06-11 Sphingotec Gmbh A method for diagnosing or monitoring kidney function or diagnosing kidney dysfuntion
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
WO2019034332A1 (en) * 2017-08-18 2019-02-21 Cambridge Enterprise Limited MODULAR BINDING PROTEINS
CN111511390A (zh) 2017-09-25 2020-08-07 艾德里诺医药公司 用于治疗或预防疾病症状的抗肾上腺髓质素(adm)结合剂
US20220268761A1 (en) 2017-10-18 2022-08-25 Adrenomed Ag Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder
JP7411546B2 (ja) 2017-10-24 2024-01-11 シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 初回心血管イベントの予測のためのセレノプロテインp
KR20200083509A (ko) 2017-10-25 2020-07-08 4틴4 파마슈티컬스 게엠베하 특이적 dpp3-에피토프에 대하여 지시되고 이에 결합하는 dpp3 결합제 및 산화적 스트레스와 연관되는 질환 / 급성 병태의 예방 또는 치료에서의 그의 용도
KR20200135947A (ko) 2018-02-08 2020-12-04 스핑고텍 게엠베하 치매의 진단 및/또는 예측을 위한 아드레노메둘린 (adm) 및 치매의 요법 또는 예방에 사용하기 위한 항-아드레노메둘린 결합제
EP3569614A1 (en) 2018-05-18 2019-11-20 Julius-Maximilians-Universität Würzburg Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
EP3586865A1 (en) 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
JP2022502367A (ja) 2018-09-24 2022-01-11 エアーピオ ファーマシューティカルズ, インコーポレイテッド HPTP−β(VE−PTP)およびVEGFを標的にする多特異性抗体
AU2019408553A1 (en) 2018-12-20 2021-06-17 Sphingotec Gmbh Selenoprotein P in heart failure
CN113557031A (zh) 2018-12-21 2021-10-26 4Teen4制药有限公司 使用血管紧张肽受体激动剂和/或其前体的治疗的疗法指导和/或疗法监测
CA3139051A1 (en) 2019-06-04 2020-12-10 Christian REICHEN Multispecific proteins
EP4014049A1 (en) 2019-08-15 2022-06-22 sphingotec GmbH A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction in pediatric patients
EP4021571A1 (en) 2019-08-30 2022-07-06 4TEEN4 Pharmaceuticals GmbH Therapy guidance and/or therapy monitoring for treatment of shock
AU2020399230A1 (en) 2019-12-11 2022-06-23 Molecular Partners Ag Recombinant peptide-MHC complex binding proteins and their generation and use
EP3871689A1 (en) 2020-02-26 2021-09-01 sphingotec GmbH Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
IL295728A (en) 2020-02-27 2022-10-01 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm backbone without ig for use in the treatment of cure or prevention of shock
JP2023515985A (ja) 2020-02-27 2023-04-17 アドレノメト アクチェンゲゼルシャフト ショック状態の患者の治療において使用するための抗アドレノメデュリン(adm)結合剤
WO2021170838A1 (en) 2020-02-27 2021-09-02 4TEEN4 Pharmaceuticals GmbH Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock
US20210285949A1 (en) 2020-03-16 2021-09-16 Sphingotec Gmbh Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin
EP3922993A1 (en) 2020-06-12 2021-12-15 4TEEN4 Pharmaceuticals GmbH Dpp3 in patients infected with coronavirus
WO2021185786A1 (en) 2020-03-16 2021-09-23 4TEEN4 Pharmaceuticals GmbH Dpp3 in patients infected with coronavirus
CR20220618A (es) 2020-05-06 2023-01-19 Molecular Partners Ag Nuevas proteinas de unión a repeticiones de anquirina y sus usos
BR112022023049A2 (pt) 2020-05-14 2022-12-20 Molecular Partners Ag Proteínas multiespecíficas
EP4023218A1 (en) 2020-12-02 2022-07-06 S-Form Pharma Combination therapy for patients having acute and/or persistent dyspnea
AU2021403833A1 (en) 2020-12-16 2023-07-27 Molecular Partners Ag Novel slow-release prodrugs
AU2022233791A1 (en) 2021-03-09 2023-09-28 Molecular Partners Ag Novel darpin based cd123 engagers
AU2022231913A1 (en) 2021-03-09 2023-09-28 Molecular Partners Ag Novel darpin based cd33 engagers
MX2023010543A (es) 2021-03-09 2023-10-13 Molecular Partners Ag Ligadores multiespecificos de celulas t novedosos basados en darpin.
WO2022190008A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Protease cleavable prodrugs
WO2022263648A1 (en) 2021-06-18 2022-12-22 Sphingotec Gmbh A method for predicting sepsis and septic shock
EP4363859A1 (en) 2021-06-29 2024-05-08 berYsol GmbH Composite biomarker for the identification of selenium deficiency in a bodily fluid
EP4145456A1 (en) 2021-09-06 2023-03-08 Bayer AG Prediction of a change related to a macular fluid
WO2023110983A1 (en) 2021-12-14 2023-06-22 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use
WO2023175035A1 (en) 2022-03-15 2023-09-21 Adrenomed Ag Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment
WO2024023369A1 (en) 2022-07-29 2024-02-01 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
WO2024023368A1 (en) 2022-07-29 2024-02-01 4TEEN4 Pharmaceuticals GmbH Prediction of an increase of dpp3 in a patient with septic shock
WO2024028278A1 (en) 2022-08-01 2024-02-08 Molecular Partners Ag Charge modified designed repeat domains and their use
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules
WO2024059686A2 (en) * 2022-09-15 2024-03-21 The Regents Of The University Of California Darpin backbones and rigidified electron microscopy imaging scaffolds
WO2024126793A1 (en) 2022-12-15 2024-06-20 4TEEN4 Pharmaceuticals GmbH Dpp3 inhibitor for improvement of pulmonary function in critically ill patients

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1892296A1 (en) 1988-09-02 2008-02-27 Dyax Corporation Generation and selection of recombinant varied binding proteins
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
ES2273415T3 (es) 1997-04-07 2007-05-01 Genentech, Inc. Anticuerpos anti-vegf.
DE69842174D1 (de) 1997-04-07 2011-04-21 Genentech Inc Verfahren zur Herstellung humanisierter Antikörper durch randomisierte Mutagenese
JP4086325B2 (ja) 1997-04-23 2008-05-14 プリュックテュン,アンドレアス 標的分子と相互作用する(ポリ)ペプチドをコードする核酸分子の同定方法
US6416950B1 (en) 1998-12-02 2002-07-09 Phylos, Inc. DNA-protein fusions and uses thereof
NZ515913A (en) 1999-06-08 2004-01-30 Regeneron Pharma Modified chimeric polypeptides with improved pharmacokinetic properties
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
WO2002020565A2 (en) * 2000-09-08 2002-03-14 Universität Zürich Collections of repeat proteins comprising repeat modules
RU2299208C2 (ru) * 2001-05-08 2007-05-20 Шеринг Акциенгезельшафт Антраниламидпиридинамиды избирательного действия в качестве ингибиторов vegfr-2 и vegfr-3
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
KR20060129246A (ko) * 2003-12-05 2006-12-15 컴파운드 쎄라퓨틱스, 인크. 타입 2 혈관 내피 성장 인자 수용체의 억제제
EA013615B1 (ru) * 2004-11-12 2010-06-30 Байер Шеринг Фарма Акциенгезельшафт Рекомбинантный онколитический парамиксовирус и его применение
US20060217311A1 (en) * 2005-03-25 2006-09-28 Daniel Dix VEGF antagonist formulations
NZ564695A (en) 2005-07-08 2009-02-28 Univ Zuerich Phage display using cotranslational translocation of fusion polypeptides
CA2670471A1 (en) 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
WO2008094969A2 (en) * 2007-02-01 2008-08-07 Genentech, Inc. Combination therapy with angiogenesis inhibitors
US20100144599A1 (en) 2007-02-02 2010-06-10 Bristol-Myers Squibb Company Vegf pathway blockade

Also Published As

Publication number Publication date
RU2011122201A (ru) 2012-12-10
IL212589A (en) 2017-01-31
JP6329503B2 (ja) 2018-05-23
US8901076B2 (en) 2014-12-02
RU2650765C1 (ru) 2018-04-17
CA2742241A1 (en) 2010-06-03
CN107011425A (zh) 2017-08-04
KR101698362B1 (ko) 2017-01-20
CA2742241C (en) 2019-12-10
CN102272148A (zh) 2011-12-07
JP2015133978A (ja) 2015-07-27
AU2009319204B2 (en) 2014-11-13
NZ592591A (en) 2012-04-27
EP2358746A1 (en) 2011-08-24
EP3785735A1 (en) 2021-03-03
RU2550258C2 (ru) 2015-05-10
JP2012507271A (ja) 2012-03-29
KR20110082528A (ko) 2011-07-19
JP5954990B2 (ja) 2016-07-20
WO2010060748A1 (en) 2010-06-03
MX2011004649A (es) 2011-05-30
IL212589A0 (en) 2011-07-31
DK2358746T3 (da) 2020-12-21
BRPI0921469B1 (pt) 2022-01-18
AU2009319204A1 (en) 2010-06-03
ES2836948T3 (es) 2021-06-28
MX359570B (es) 2018-10-01
US20150344539A1 (en) 2015-12-03
US20110207668A1 (en) 2011-08-25
CN107011425B (zh) 2021-01-01
EP2358746B1 (en) 2020-09-16

Similar Documents

Publication Publication Date Title
BRPI0921469A2 (pt) proteínas de ligação que inibem a interação com o receptor de vegf-a
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0922505A2 (pt) proteínas de ligação a receptor cgrp humano
IS8842A (is) Kjarnviðtaka bindimiðlar.
IL222749A0 (en) Modified binding proteins inhibiting the vegf-a receptor interaction
NO20072812L (no) Forbedret oreenhet
ATE509022T1 (de) Nikotin-acetylcholin-rezeptorsubtyp-selektive diazabicycloalkanamide
BRPI0720699A2 (pt) Programas ligados
NO20074696L (no) Aktiveringsmekanisme
BRPI0910835A2 (pt) conjunto com pílulas hemostáticas e radiograficamente detectáveis
DE602008004276D1 (de) Luftkanone
BRPI0913515A2 (pt) fechamento com mecanismo limitador
BRPI0919024A2 (pt) compostos que seletivamente modulam o receptor cb2
SE0850135L (sv) Häftapparat
BRPI0909289A2 (pt) Mistura simbiótica
BRPI0913513A2 (pt) fechamento com mecanismo limitador
ATE539819T1 (de) Elektronisch gesteuertes zapfenbelastungssystem
BRPI0812991A2 (pt) Utilização de combustível melhorado
DK2126380T3 (da) Rillet befæstigelseselement
DE602008005825D1 (de) Luftdruckwaffe
BRPI0914557A2 (pt) proteína de ligação de biotina modificada
FI20080585A (fi) Telkimekanismi
DE602007008589D1 (de) Pyridooxazepin-progesteronrezeptor-modulatoren
DE112008001259A5 (de) Dosiermagnet
BRPI0817449A2 (pt) Composição de combustível

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/11/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.